Prochlorperazine

Quick links to important sections

Prochlorperazine

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prochlorperazine

Quick Facts

Property Description
Active ingredient Prochlorperazine (INN)
Form Tablet, Suppository, Solution for Injection
Pharmacological class First-Generation Antipsychotic (FGA)
Common use Antiemetic (sickness control)
Origin Synthetic Compound (Phenothiazine derivative)

What Type of Medicine is Prochlorperazine?

Prochlorperazine is a powerful, synthetic compound chemically classified as a phenothiazine derivative. It is formally recognized as a First-Generation Antipsychotic (FGA), or neuroleptic drug. Its classification as a high-potency agent is widely recognized in pharmacological studies, distinguishing it from lower-potency phenothiazine derivatives. This medicine's identity is defined by its single active component, Prochlorperazine (INN), which belongs to the piperazine chemical subclass of phenothiazines. The primary pharmacological classification establishes the drug’s fundamental range of action on the central nervous system, distinguishing it as a substance that influences major nerve signaling pathways, particularly those involving dopamine.

General Purpose: Antiemetic and Neuroleptic Action

The general purpose of Prochlorperazine is defined by its dual therapeutic classification: it functions as both a potent antiemetic and a neuroleptic agent. This medication is used to control severe sickness and assist in stabilizing thought and perception. This dual classification allows it to manage conditions involving severe mental distress as well as acute episodes of sickness where prompt relief is necessary. As an antiemetic, it helps to rapidly quiet signals that cause severe sickness, while its neuroleptic function assists in stabilizing nerve pathways related to disorganized thought and extreme emotional states.

Composition and Available Forms

Prochlorperazine is manufactured exclusively as a single active ingredient product, ensuring its efficacy is solely derived from the Prochlorperazine compound. This medicine is available in several pharmaceutical preparations to accommodate varying clinical needs, including standard tablets for oral use, suppositories for rectal administration, and a sterile solution for injection for parenteral delivery. The need for rapid systemic entry in acute clinical situations is supported by its consistent availability in a sterile solution for injection. The availability of these distinct forms allows medical professionals to select the most appropriate method—oral, rectal, or injection—based on the patient's immediate clinical status and necessity for rapid onset of effect.

Regulatory References

  1. Prochlorperazine (MedlinePlus/NIH)

What side effects are possible with Prochlorperazine?

Possible Side Effects and Safety Information

Official regulatory documents classify the adverse effects of Prochlorperazine based on frequency and affected system-organ classes. As a Phenothiazine derivative with neuroleptic activity, its safety profile is characterized by effects on the central nervous and cardiovascular systems.


Common and Expected Adverse Reactions

The most frequently documented effects are classified as Common and include drowsiness (sedation), dry mouth, dizziness, constipation, and orthostatic hypotension (a drop in blood pressure upon standing). Effects related to muscle control, known as Extrapyramidal Symptoms (EPS), such as acute dystonia and akathisia, are also commonly listed, especially more common during the initiation of treatment or dose increases.

Uncommon effects documented in regulatory labeling may include certain skin reactions and difficulty with urination.


Serious Safety Considerations

Regulatory sources explicitly highlight rare but severe adverse reactions. These include Neuroleptic Malignant Syndrome (NMS), a potentially life-threatening reaction, and severe blood dyscrasias, such as agranulocytosis. The risk of Tardive Dyskinesia (TD), a movement disorder, is associated with long-term exposure to the medication.

Furthermore, official documentation identifies specific safety considerations for certain patient groups. A critical caution is issued for the use of this class of medicine in older adults with dementia-related psychosis, due to a documented increased risk of death in this specific population. The medicine is also contraindicated in states of severe central nervous system (CNS) depression or known phenothiazine hypersensitivity.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Prochlorperazine overdose describes a risk of severe, life-threatening manifestations affecting multiple physiological systems.

Feature Regulatory Description
Documented overdose presentations Overdose manifestations include central nervous system depression leading to coma, convulsions (seizures), drowsiness, confusion, disorientation, agitation, and severe Extrapyramidal Symptoms (EPS). Other signs include hypothermia or hyperpyrexia, and autonomic symptoms like blurred vision, dry mouth, and urinary retention.
Physiological systems affected Central Nervous System, Cardiovascular System (risk of cardiac arrhythmias and severe hypotension), and Neuromuscular System.

Official Overdose Statements

  • Overdose may present with severe CNS depression, including coma, along with cardiovascular instability such as severe hypotension and cardiac arrhythmias.
  • A major, life-threatening manifestation documented in the overdose context is Neuroleptic Malignant Syndrome (NMS), which requires immediate and intensive management.
  • No specific antidote is known for Prochlorperazine overdose; management is symptomatic and supportive.
  • If overdose is suspected, seek immediate medical attention and call a poison control center immediately.

Connection to the overall overdose profile (2–4 sentences): Government regulatory documents define the overdose profile through the explicit enumeration of severe clinical effects, highlighting the potential for life-threatening outcomes such as NMS and severe hypotension. This documented severity directly establishes the condition under which immediate medical help must be sought, which is mandated for any suspected overdose event due to the lack of a specific antidote and the requirement for intensive hospital monitoring.

Therapeutic Uses of Prochlorperazine

What Prochlorperazine Treats: Main Uses and Benefits

The medication is commonly used in therapeutic contexts involving severe physical distress (sickness and dizziness) and acute mental health symptoms. It is generally used to help manage symptoms such as nausea and vomiting, dizziness, or a spinning sensation (vertigo), and symptoms related to balance issues like those seen in Ménière's disease. The medication is relevant for easing symptom clusters that may become intense or disruptive, including acute sickness following surgery or symptoms associated with chemotherapy, as well as severe agitation in certain psychiatric conditions. The therapeutic benefit is that it supports the patient during difficult episodes by contributing to easing the overall symptom load associated with these conditions.

“This medication is applied across domains where short-term symptomatic assistance is needed to address pronounced manifestations like severe sickness or balance loss.”

Symptomatic Relief Categories

The primary symptomatic domains where Prochlorperazine is applied include: symptoms related to physical discomfort (nausea and vomiting), symptoms linked to systemic imbalance (vertigo and dizziness), and symptoms associated with acute or episodic changes (agitation/psychotic manifestations). This assists with supporting functional stability when symptoms temporarily escalate or interfere with daily functioning.


Quick Fact: Support for Severe Nausea and Vertigo


Eligibility and Restrictions for Use

The eligibility to use Prochlorperazine is strictly defined by regulatory documents, which establish clear population constraints and absolute prohibitions. Use is generally established in adults and in children who are two years of age or older, or who weigh at least 9.1 kg (20 lb). Use is otherwise contraindicated in children who are younger than two years of age.

The medicine is contraindicated in several specific populations. This includes individuals with a known hypersensitivity to prochlorperazine or other phenothiazine derivatives. It must not be used in patients in comatose states, with severe Central Nervous System (CNS) depression, blood dyscrasias, or a history of severe liver disease. Use is also prohibited in patients with pheochromocytoma or in the postoperative management following pediatric surgery.

Specific restrictions apply to other groups. The medicine is contraindicated during the third trimester of pregnancy due to the risk of extrapyramidal and withdrawal symptoms in the neonate, and its use is not recommended during lactation. Caution is required for older adults due to potential increased sensitivity and for patients with cardiovascular impairment, narrow-angle glaucoma, or a history of epilepsy, as the medicine may lower the seizure threshold.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The official regulatory documentation for Prochlorperazine establishes specific constraints for co-administration with other substances, primarily focused on pharmacodynamic reinforcement and documented contraindications.


Documented Interaction Classes

The regulatory profile identifies several drug categories and specific medicines that have officially documented interactions, requiring caution or avoidance.

  • Central Nervous System (CNS) Depressants: Co-administration is contraindicated in the presence of large amounts of CNS depressants, including alcohol, narcotics, and barbiturates, due to the intensification of their effects.
  • Specific QTc-Prolonging Agents: The risk of serious ventricular arrhythmias is increased when combined with certain QTc-prolonging drugs, leading to avoidance or contraindication for agents like pimozide and thioridazine.
  • Anticholinergics and Antihypertensives: Co-administration may result in an additive effect of anticholinergic activity or an exaggeration of hypotensive effects, respectively.

Exposure and Administration Constraints

Interactions also include specific restrictions regarding timing and management:

  • Food Interaction: For the sustained-release capsule form, co-administration with food slows absorption, resulting in a documented reduction in the maximum plasma concentration ( C max) and overall exposure (AUC).
  • Epinephrine Prohibition: Epinephrine must not be used to treat hypotension induced by phenothiazines due to a paradoxical effect that can further lower blood pressure.
  • Metrizamide Rule: Administration of Prochlorperazine must be discontinued 24 hours prior to the use of the contrast agent metrizamide.

Mechanism of Action

Prochlorperazine is a piperazine phenothiazine that exerts its action by functioning as an antagonist at several neurotransmitter receptors within the central nervous system, leading to a modulation of overactive or dysregulated physiological processes.

Dopamine Receptor Antagonism

Prochlorperazine acts by blocking D2 dopamine receptors, particularly within the chemoreceptor trigger zone (CTZ). This antagonism interrupts the signaling sequence between the CTZ and the vomiting center, thereby modulating signaling activity that originates in this pathway.


Multireceptor Pathway Modulation

Beyond its primary dopaminergic effects, the compound engages mechanisms that involve antagonism at other G-protein coupled receptors, including alpha1-adrenergic, histamine (H1), and muscarinic (cholinergic) receptors. This broad engagement affects multiple layers of pathway activation, inducing secondary effects, including alpha1-adrenergic antagonism and resultant smooth muscle activity changes, and inducing antagonistic effects at muscarinic and H1 receptors.

Dosage and Administration Information

Instruction Map: How to use Prochlorperazine

This map summarizes the administration guidelines for prochlorperazine.


Administration Scope

Feature Rule Description
Route of administration Oral (tablet, extended-release capsule), Rectal (suppository), Intramuscular (IM) injection, and Intravenous (IV) injection. Subcutaneous administration is not advisable.
Dosing schedule Antiemetic Use: Oral dose is typically 5–10 mg three or four times daily (maximum 40 mg per day). The rectal suppository is 25 mg administered twice daily. Anxiety: Maximum oral dose is 20 mg per day.
Timing in relation to meals (if applicable) Buccal tablets are recommended to be taken after meals to facilitate dissolution under the lip or gum.
Preparation requirements (if applicable) The IV solution may be administered undiluted or diluted in isotonic solution.
Age-group administration rules Pediatric: Use is not recommended in children under 2 years of age or weighing less than 9 kg (20 lbs). Older Adults/Geriatric: A lower initial dosage is necessary, and dose adjustments must be made more gradually.
Special procedural conditions IV Rate: The injection must be administered slowly, not exceeding 5 mg per minute. IM Site: The injection must be administered deeply into the upper, outer quadrant of the buttock. Duration: Treatment for non-psychotic anxiety must not exceed 12 weeks.

Instruction Classifications

Classification Rule Summary
Administration method type Oral, Rectal, and Parenteral (IM and IV).
Frequency pattern Fixed Multiple Doses (up to four times daily), Twice Daily Dosing, and As-Needed dosing for acute episodes.
Use-context constraints Duration is limited for anxiety, and maximum daily dose restrictions apply for approved indications.

Connection to the overall use protocol

The instructions define a comprehensive administration protocol that specifies the route, dosage limits, and frequency based on the condition being managed. These constraints, such as the maximum daily dose for antiemetic use and the time limit for anxiety treatment, govern the standardized use of the medicine. The protocols also mandate specific injection techniques and rate restrictions to ensure proper delivery of the parenteral forms.

Recent Clinical Evidence

Research evidence / Overview of studies for Prochlorperazine


Evidence for use in Controlling Severe Sickness and Vomiting

Prochlorperazine was studied for conditions characterized by fluctuating or episodic manifestations, such as conditions associated with acute or disruptive episodes. Randomized Controlled Trials (RCTs) were the main study type used to monitor outcomes related to physical discomfort, such as the reported intensity of nausea and the frequency of vomiting episodes. Studies monitored short time intervals, typically observing patient responses over 30, 60, or 120 minutes following administration.

Findings indicate patterns related to outcomes describing episodic or acute changes as measured during the study period. This evidence contributes to the broader evidence landscape for conditions associated with acute or disruptive episodes.

What remains uncertain is the long-term profile of use. Research provides limited context for patients needing assistance over many weeks or months for recurrent conditions.


Evidence for use in Managing Psychotic Symptoms

This section will outline the historical regulatory studies and long-term observational research that established the evidence base for Prochlorperazine's use as a First-Generation Antipsychotic (FGA) in patients with schizophrenia and related psychotic conditions.

Research explored how the medicine was evaluated in studies involving conditions characterized by fluctuating or episodic manifestations, such as schizophrenia. The evidence base includes a set of historical regulatory studies and long-term observational studies that monitor outcomes reflecting daily functioning and overall symptom severity.

Evidence quality varies across studies. The body of research includes historical trials and newer systematic reviews. Limited information is available regarding the long-term outcomes of this class of medicine when compared to more recently developed treatments.


Evidence in Specific Patient Populations

Prochlorperazine was studied for pediatric populations involving outcomes related to physical discomfort and fluctuating or episodic manifestations. However, the available data show patterns related to specific age groups. Data for children under two years of age or under 20 pounds are not included in the evidence base.

While research examined adults of varying ages, there is limited specialized information exploring how outcomes related to physical discomfort or systemic imbalance may differ specifically in older adults presenting with multiple other conditions.

Key Studies & References

  1. NICE Guideline NG180: Nausea and vomiting (adults) - Management of nausea and vomiting in adults

Frequently Asked Questions (FAQ)

Common questions about Prochlorperazine (FAQ)


Q: How quickly does Prochlorperazine start working for nausea?

A: Official product information describes the expected time it takes for Prochlorperazine to begin working, which varies based on the form used. Following oral administration, onset of action is generally described as 30 to 40 minutes. For the rectal form, the effect may be noted in approximately 60 minutes, and intramuscular injection typically begins working in 10 to 20 minutes.

Q: How long does the effect of Prochlorperazine usually last?

A: The effect of the medicine is generally described in official product information as lasting for approximately 3 to 4 hours. This duration is typical across all authorized routes of administration.

Q: Why is Prochlorperazine sometimes prescribed for anxiety or vertigo?

A: Prochlorperazine is officially indicated for the short-term management of non-psychotic generalized anxiety. The FDA label does not include vertigo. However, its mechanism of action, which involves blocking dopamine receptors, influences pathways that are related to balance signals.

Q: What is the difference between Prochlorperazine tablets and suppositories?

A: The main difference between Prochlorperazine tablets and suppositories is the administration route (oral versus rectal). This difference in route leads to distinctions in the amount of drug in each unit, and also affects the expected onset time, with suppositories generally taking longer to begin working than the oral form, according to product information.

Q: Can Prochlorperazine affect the heart or heart rhythm?

A: Official warnings state that Prochlorperazine is associated with a risk of cardiac arrhythmias (irregular heart rhythm) and changes in heart activity. Official documents state that caution is required for individuals with pre-existing cardiovascular impairment.

Q: Are headaches a common side effect of Prochlorperazine?

A: Headache is described in official drug information as a possible side effect of Prochlorperazine.

Q: Is it possible to become dependent on Prochlorperazine?

A: According to official regulatory sources, Prochlorperazine is not classified as a controlled substance by the US Drug Enforcement Administration (DEA). This classification suggests a low potential for abuse or dependence.

Q: Is Prochlorperazine a drug that can be crushed or split?

A: Official regulatory documents caution that solid dose forms of Prochlorperazine, such as tablets, should not be altered unless specific instruction is provided. This precaution is in place because altering the form may lead to dosing errors.

Q: Does Prochlorperazine interact with caffeine?

A: While caffeine is not typically listed as a primary interaction, official regulatory documents note that it may be used during the supportive treatment of an overdose. In this clinical context, caffeine has been noted as a supportive measure intended to address central nervous system (CNS) depression.

Q: Is there a generic version of Prochlorperazine available?

A: Yes, official drug information confirms that Prochlorperazine is widely available as a generic prescription medication.

Q: Is Prochlorperazine used for migraine headaches?

A: The main official indication for Prochlorperazine is severe nausea and vomiting. However, official information acknowledges that the medication is sometimes used in certain acute care settings in the context of acute migraines.

Q: Can Prochlorperazine cause weight gain?

A: Official product information indicates that weight gain is listed as a possible side effect of Prochlorperazine.

Q: Is Prochlorperazine a type of antihistamine?

A: Prochlorperazine is chemically classified as a phenothiazine derivative and a First-Generation Antipsychotic. Although it affects certain histamine receptors ( H1 receptors), its primary classification and intended use are not those of a traditional antihistamine.

Q: Can Prochlorperazine cause sensitivity to sunlight?

A: Official regulatory documents list an increased sensitivity of the skin to sunlight (known as photosensitivity) as a possible side effect of Prochlorperazine.

Q: Is Prochlorperazine a controlled substance?

A: Prochlorperazine is not classified as a controlled substance by the US Drug Enforcement Administration (DEA) or other major regulatory bodies.

Q: Are there specific vitamins or supplements that interact with Prochlorperazine?

A: Official drug labels state that there is a potential for interaction with various substances, including prescription and over-the-counter medicines, vitamins, and herbal products. Official documents emphasize the importance of communicating all product information to a prescribing professional.

Q: Are there different brand names for Prochlorperazine?

A: While it is typically available as the generic Prochlorperazine, official sources indicate that Compazine was a former common brand name for this medication.

Q: How is Prochlorperazine usually eliminated from the body?

A: Pharmacokinetic data indicates that Prochlorperazine distributes to body tissues and is excreted primarily in the feces. The medicine is also subject to enterohepatic circulation, meaning it is absorbed, passes through the liver, and can be reabsorbed by the intestine.

Q: Is it possible to take too much Prochlorperazine?

A: Yes, official product warnings state that taking too much Prochlorperazine is possible and can lead to overdose. Symptoms can include severe central nervous system depression, seizures, and potentially severe effects on the heart, such as cardiac arrhythmias and severe hypotension.

Q: What are the common signs of stopping Prochlorperazine suddenly?

A: Official FDA label information notes that in patients who have been taking Prochlorperazine long-term, suddenly stopping the medication may cause temporary discontinuation symptoms. These symptoms can include nausea, vomiting, dizziness, and tremulousness (tremors).

Q: Does Prochlorperazine have a risk of causing vision changes?

A: Possible side effects listed in official drug information include temporary blurred vision and, in rare circumstances, vision loss.

Q: What is the risk of Prochlorperazine causing allergic reactions?

A: The risk of allergic reaction exists, as official regulatory documents list known hypersensitivity (severe allergic reaction) to Prochlorperazine or other similar medicines as a contraindication. A contraindication is a specific condition or factor that serves as a reason not to take the medicine.

Q: Is Prochlorperazine used for vomiting after surgery?

A: Official documentation establishes that the use of Prochlorperazine is prohibited in the post-operative management following pediatric surgery. The label does not specifically address its use in adult post-operative vomiting.

Q: Can Prochlorperazine make certain other side effects worse?

A: Official warnings state that Prochlorperazine may intensify or prolong the action of central nervous system depressants when taken together. Additionally, it can result in additive effects when combined with anticholinergic medicines, which means the effects of both drugs are summed together.

How should Prochlorperazine be stored and disposed of?

Official Storage and Disposal Instructions

Storage of Prochlorperazine must strictly adhere to the conditions mandated by official regulatory labeling, which vary by formulation.

Formulation Required Storage Condition Container/Handling Rules
Oral Tablets/Capsules Store at controlled room temperature (15 C to 30 C) Must be protected from light and dispensed in a tight, light-resistant container.
Suppositories Store at controlled room temperature or refrigerated; Do not freeze Must not be removed from the wrapper until ready for use.
Injection Solution Store at controlled room temperature (20 C to 25 C); Do not freeze Keep in the original carton until the time of use.

The medication must, in all forms, be stored out of the reach of children, and tablets require safety closures on the container. Disposal of unused or expired Prochlorperazine must follow federal, state, and local disposal regulations. Some official guidelines specify that unused medicine can be flushed down the toilet if a take-back program is unavailable.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prochlorperazine found in:

A-Z Index: